Colorectal News and Research

RSS

Research roundup: Hospital emergency room HIV screenings; Medical device reviews; Health law impact on docs and hospitals

Physician Satisfaction With Chronic Care Processes: A Cluster-Randomized Trial Of Guided Care - The authors randomly assigned teams of physicians and their chronically ill older patients into groups that either provided Guided Care - an educated registered nurse works with a primary care practice team to enhance quality of care - or usual care. One year later, they measured "physicians' satisfaction with chronic care processes, time spent on chronic care, knowledge of their chronically ill older patients, and care coordination provided by physicians and office staff."

26 Jul 2010

Genomics researchers study role of protein in metabolic disorders, heart disease

Studying a protein already known to play an important role in type 2 diabetes and cancer, genomics researchers have discovered that it may have an even broader role in disease, particularly in other metabolic disorders and heart disease. In finding unsuspected links to other disease-related genes, the scientists may have identified future targets for drug treatments.

22 Jul 2010

Lack of insurance coverage and fees deter willingness to undergo CTC for colorectal cancer screening

A recent questionnaire submitted to a group of patients at one of the nation's largest general hospitals suggests that a significant number of patients, who have previously refused colorectal cancer screening, are willing to undergo computed tomography colonography (CTC) (or virtual colonoscopy), but not willing to pay for the exam themselves when not covered by insurance, according to a study in the August issue of the American Journal of Roentgenology (www.ajronline.org).

22 Jul 2010

TCF7L2 protein may play important role in heart disease, other metabolic disorders: Researchers

22 Jul 2010

Affymetrix second-quarter total revenue decreases to $71.7 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

22 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Rate of women getting mammography screenings stalls; colorectal cancer screenings remain underused by medicare patients

One-fifth of American women ages 50 to 74 have fallen behind on mammography screenings for breast cancer, the Centers for Disease Control and Prevention are reporting. Although the percentage of women in this age group who get a regular breast cancer screening every two years increased steadily during the 1990s, the rate has remained just over 80 percent since 2000, according to the centers' Morbidity and Mortality Weekly Report.

21 Jul 2010

Researchers receive $12M NCI grant to identify biological pathways that lead to prostate cancer risk

Researchers at the USC Norris Comprehensive Cancer Center have received a $12 million National Cancer Institute grant to lead a multi-institution international project aimed at identifying new biological pathways critical to the development and potential treatment of prostate cancer.

21 Jul 2010

ARUP announces new version of Septin 9 methylated DNA test

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced it is offering the Septin 9 methylated DNA test, a new blood-based colorectal cancer screening method. While ARUP is not the first laboratory to offer this test, this new version, developed and validated independently by ARUP, is clinically proven to detect a higher proportion of colorectal cancers than Septin 9 tests developed by other companies.

20 Jul 2010

Combined technologies offer promise for detecting colon cancer in women

A team led by a Northwestern University biomedical engineer has found that combining novel optical technologies with a common colon cancer screening test may allow doctors to more accurately detect the presence of colon cancer, particularly in women.

20 Jul 2010

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed.

17 Jul 2010

Proton therapy treatment for anal canal cancer performed for first time in US

The INTEGRIS Cancer Institute of Oklahoma and the ProCure Proton Therapy Center announce a breakthrough treatment approach for anal canal cancer. For the first time in the United States proton therapy is now being used to treat this type of cancer.

17 Jul 2010

NEOP receives stockholder approval to increase company shares to 205 milliion

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.

17 Jul 2010

An overview of AAPM annual meeting

AAPM is the premier organization in medical physics, a broadly-based scientific and professional discipline encompassing physics principles and applications in medicine and biology. Its membership includes medical physicists who specialize in research that develops cutting-edge technologies and board-certified clinical medical physicists who apply these technologies in community hospitals, clinics, and academic medical centers.

16 Jul 2010

Survival rates of nine types of cancer in Spain

Spanish epidemiologists have presented information on survival of nine types of cancer in Spain and have compared it with other European countries. At five years from diagnosis, the lowest survival rate is observed in lung cancer (less than 11%), and the highest in testicular cancer (95%). Cancer survival in Spain is at the European average.

16 Jul 2010

UCI first medical center on West Coast to perform robotic thyroidectomies

UC Irvine Healthcare is the first medical center on the West Coast and the only one in California to perform robotic thyroidectomies, a procedure that removes the diseased gland without leaving a visible scar on the neck. Dr. Jason Kim, associate clinical professor of otolaryngology and a head and neck cancer specialist, has performed robotic-assisted surgery using the daVinci Surgical System on three patients with thyroid tumors.

16 Jul 2010

Study results to help researchers better understand cancer genetics, improve treatment regimens

The largest study to correlate genetics with response to cancer drugs releases its first results today. The researchers behind the study, based at Massachusetts General Hospital Cancer Center and the Wellcome Trust Sanger Institute, describe in this initial dataset the responses of 350 cancer samples to 18 anticancer therapeutics.

16 Jul 2010

PSA test reduces prostate cancer death rate by nearly 50%: NCI

The nation's leading authority on cancer has thrown out its own study on prostate cancer screening, now saying that PSA testing reduces the prostate cancer death rate by nearly 50 percent.

16 Jul 2010

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies.

15 Jul 2010

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.

14 Jul 2010

Colorectal News and Research

Research roundup: Hospital emergency room HIV screenings; Medical device reviews; Health law impact on docs and hospitals

Genomics researchers study role of protein in metabolic disorders, heart disease

Lack of insurance coverage and fees deter willingness to undergo CTC for colorectal cancer screening

TCF7L2 protein may play important role in heart disease, other metabolic disorders: Researchers

Affymetrix second-quarter total revenue decreases to $71.7 million

Researchers find that increase in leptin may promote colorectal neoplasms

Rate of women getting mammography screenings stalls; colorectal cancer screenings remain underused by medicare patients

Researchers receive $12M NCI grant to identify biological pathways that lead to prostate cancer risk

ARUP announces new version of Septin 9 methylated DNA test

Combined technologies offer promise for detecting colon cancer in women

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

Proton therapy treatment for anal canal cancer performed for first time in US

NEOP receives stockholder approval to increase company shares to 205 milliion

An overview of AAPM annual meeting

Survival rates of nine types of cancer in Spain

UCI first medical center on West Coast to perform robotic thyroidectomies

Study results to help researchers better understand cancer genetics, improve treatment regimens

PSA test reduces prostate cancer death rate by nearly 50%: NCI

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News